<DOC>
	<DOCNO>NCT03015883</DOCNO>
	<brief_summary>A unique approach cancer treatment employ intratumoral diffuse alpha radiation emitter device .</brief_summary>
	<brief_title>Alpha Radiation Emitters Device Treatment Squamous Cell Carcinoma</brief_title>
	<detailed_description>This prospective , first man , control study , assess safety efficacy diffuse alpha emitter radiation therapy ( DaRT ) deliver radioactive wire insert tumor . This approach combine advantage local intratumoral irradiation tumor , use conventional brachytherapy , power alpha radiation emit atom , introduce quantity considerably low radiation therapy already use patient . Lesions histopathological diagnosis squamous cell carcinoma study . Reduction tumor size 30 day DaRT insertion assess . Safety assess incidence , severity frequency Adverse Events ( AE ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>1 . Histopathological confirmation squamous cell carcinoma . 2 . Tumor size &lt; /= 5 centimeter longest diameter 3 . Age 18 4 . Women childbearing age evidence negative pregnancy test 5 . Life expectancy 6 month . 6 . Performance status 2 ( ECOG scale ) less 7 . Signed informed consent form 1 . Tumor maximal diameter &gt; 5 centimeter 2 . Ulcerative lesion 3 . Tumor Keratoacanthoma histology 4 . Performance status &gt; 3 ( ECOG scale ) 5 . Patients moribund disease , autoimmune disease vasculitis . 6 . Patients immunosuppressive and/or corticosteroid treatment . 7 . Volunteers participate study past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Alpha emit radiation</keyword>
</DOC>